Prevalence and Risk Factors of Venous Thromboembolism in Critically Ill Patients with Severe COVID-19 and the Association between the Dose of Anticoagulants and Outcomes

1Mehta P, McAuley D, Brown M, Sanchez E, Tattersall R, Manson J, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England). 2020;395(10229):1033. Mehta P McAuley D Brown M Sanchez E Tattersall R Manson J et al COVID-19: consider cytokine storm syndromes and immunosuppression Lancet (London, England) 202039510229103310.1016/S0140-6736(20)30628-0727004532192578Search in Google Scholar

2Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, et al. Hypercoagulability of COVID‐19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. Journal of Thrombosis and Haemostasis. 2020;18(7):1738-42. Panigada M Bottino N Tagliabue P Grasselli G Novembrino C Chantarangkul V et al Hypercoagulability of COVID‐19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis Journal of Thrombosis and Haemostasis 20201871738 4210.1111/jth.1485032302438Search in Google Scholar

3Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020;7(8):e575-e82. Goshua G Pine AB Meizlish ML Chang CH Zhang H Bahel P et al Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study Lancet Haematol 202078e575 e8210.1016/S2352-3026(20)30216-7732644632619411Search in Google Scholar

4Wang L, Zhao L, Li F, Liu J, Zhang L, Li Q, Gu J, Liang S, Zhao Q, Liu J, Xu JF. Risk assessment of venous thromboembolism and bleeding in COVID‐19 patients. The Clinical Respiratory Journal. 2022 Mar;16(3):182-9.. Wang L Zhao L Li F Liu J Zhang L Li Q Gu J Liang S Zhao Q Liu J Xu JF Risk assessment of venous thromboembolism and bleeding in COVID‐19 patients The Clinical Respiratory Journal 2022 Mar163182 910.1111/crj.13467906001135060325Search in Google Scholar

5Klok FA, Kruip MJ, Van der Meer NJ, Arbous MS, Gommers DA, Kant KM, Kaptein FH, van Paassen J, Stals MA, Huisman MV, Endeman H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis research. 2020 Jul 1;191:145-7. Klok FA Kruip MJ Van der Meer NJ Arbous MS Gommers DA Kant KM Kaptein FH van Paassen J Stals MA Huisman MV Endeman H Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Thrombosis research 2020 Jul 1191145 710.1016/j.thromres.2020.04.013714671432291094Search in Google Scholar

6Tavazzi G, Civardi L, Caneva L, Mongodi S, Mojoli F. Thrombotic events in SARS-CoV-2 patients: an urgent call for ultrasound screening. Intensive Care Medicine. 2020 Jun;46(6):1121-3. Tavazzi G Civardi L Caneva L Mongodi S Mojoli F Thrombotic events in SARS-CoV-2 patients: an urgent call for ultrasound screening Intensive Care Medicine 2020 Jun4661121 310.1007/s00134-020-06040-3717544932322918Search in Google Scholar

7Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, Kucher N, Studt JD, Sacco C, Bertuzzi A, Sandri MT. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thrombosis research. 2020 Jul 1;191:9-14. Lodigiani C Iapichino G Carenzo L Cecconi M Ferrazzi P Sebastian T Kucher N Studt JD Sacco C Bertuzzi A Sandri MT Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy Thrombosis research 2020 Jul 11919 1410.1016/j.thromres.2020.04.024717707032353746Search in Google Scholar

8Grillet F, Behr J, Calame P, Aubry S, Delabrousse E. Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected by Pulmonary CT Angiography. Radiology. 2020:201544. Grillet F Behr J Calame P Aubry S Delabrousse E Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected by Pulmonary CT Angiography Radiology 202020154410.1148/radiol.2020201544723338432324103Search in Google Scholar

9Maatman TK, Jalali F, Feizpour C, Douglas 2nd A, McGuire SP, Kinnaman G, Hartwell JL, Maatman BT, Kreutz RP, Kapoor R, Rahman O. Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease 2019. Critical Care Medicine. 2020 Sep 1;48(9):e783-90. Maatman TK Jalali F Feizpour C Douglas 2nd A McGuire SP Kinnaman G Hartwell JL Maatman BT Kreutz RP Kapoor R Rahman O Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease 2019 Critical Care Medicine 2020 Sep 1489e783 9010.1097/CCM.0000000000004466730208532459672Search in Google Scholar

10Jiménez D, García-Sanchez A, Rali P, Muriel A, Bikdeli B, Ruiz-Artacho P, Le Mao R, Rodríguez C, Hunt BJ, Monreal M. Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis. Chest. 2021 Mar;159(3):1182-1196. Jiménez D García-Sanchez A Rali P Muriel A Bikdeli B Ruiz-Artacho P Le Mao R Rodríguez C Hunt BJ Monreal M Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis Chest 2021 Mar; 15931182 119610.1016/j.chest.2020.11.005767088933217420Search in Google Scholar

11Kaplan D, Casper TC, Elliott CG, Men S, Pendleton RC, Kraiss LW, et al. VTE Incidence and Risk Factors in Patients With Severe Sepsis and Septic Shock. Chest. 2015;148(5):1224. Kaplan D Casper TC Elliott CG Men S Pendleton RC Kraiss LW et al VTE Incidence and Risk Factors in Patients With Severe Sepsis and Septic Shock Chest 20151485122410.1378/chest.15-0287463103826111103Search in Google Scholar

12Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA, Yaffe MB, Moore HB, Barrett CD. Tissue plasminogen activator (tPA) treatment for COVID‐19 associated acute respiratory distress syndrome (ARDS): a case series. Journal of thrombosis and haemostasis. 2020 Jul;18(7):1752-5. Wang J Hajizadeh N Moore EE McIntyre RC Moore PK Veress LA Yaffe MB Moore HB Barrett CD Tissue plasminogen activator (tPA) treatment for COVID‐19 associated acute respiratory distress syndrome (ARDS): a case series Journal of thrombosis and haemostasis 2020 Jul1871752 510.1111/jth.14828726215232267998Search in Google Scholar

13Campbell CM, Kahwash R. Will complement inhibition be the new target in treating COVID-19–related systemic thrombosis?. Circulation. 2020 Jun 2;141(22):1739-41. Campbell CM Kahwash R Will complement inhibition be the new target in treating COVID-19–related systemic thrombosis? Circulation 2020 Jun 2141221739 4110.1161/CIRCULATIONAHA.120.04741932271624Search in Google Scholar

14Casini A, Alberio L, Angelillo-Scherrer A, Fontana P, Gerber B, Graf L, et al. Thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID-19-a Swiss consensus statement by the Working Party Hemostasis. Swiss medical weekly. 2020;150:w20247. Casini A Alberio L Angelillo-Scherrer A Fontana P Gerber B Graf L et al Thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID-19-a Swiss consensus statement by the Working Party Hemostasis Swiss medical weekly 2020150w2024710.4414/smw.2020.2024732277760Search in Google Scholar

15Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of thrombosis and haemostasis. 2020 May;18(5):1094-9. Tang N Bai H Chen X Gong J Li D Sun Z Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Journal of thrombosis and haemostasis 2020 May1851094 910.1111/jth.1481732220112Search in Google Scholar

16Rentsch CT, Beckman JA, Tomlinson L, Gellad WF, Alcorn C, Kidwai-Khan F, et al. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. BMJ (Clinical research ed). 2021;372:n311. Rentsch CT Beckman JA Tomlinson L Gellad WF Alcorn C Kidwai-Khan F et al Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study BMJ (Clinical research ed) 2021372n31110.1136/bmj.n311787667233574135Search in Google Scholar

17Carallo C, Pugliese F, Vettorato E, Tripolino C, Delle Donne L, Guarrera G, et al. Higher heparin dosages reduce thromboembolic complications in patients with COVID-19 pneumonia. Journal of Investigative Medicine. 2021;69(4):8847. Carallo C Pugliese F Vettorato E Tripolino C Delle Donne L Guarrera G et al Higher heparin dosages reduce thromboembolic complications in patients with COVID-19 pneumonia Journal of Investigative Medicine 2021694884710.1136/jim-2020-00162833758036Search in Google Scholar

18Meizlish ML, Goshua G, Liu Y, Fine R, Amin K, Chang E, et al. Intermediate‐dose anticoagulation, aspirin, and in‐hospital mortality in COVID‐19: A propensity score‐matched analysis. American journal of hematology. 2021;96(4):471-9. Meizlish ML Goshua G Liu Y Fine R Amin K Chang E et al Intermediate‐dose anticoagulation, aspirin, and in‐hospital mortality in COVID‐19: A propensity score‐matched analysis American journal of hematology 2021964471 910.1002/ajh.26102801358833476420Search in Google Scholar

19Al-Samkari H, Gupta S, Leaf RK, Wang W, Rosovsky RP, Brenner SK, et al. Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically ill patients with COVID-19. Annals of internal medicine. 2021;174(5):622-32. Al-Samkari H Gupta S Leaf RK Wang W Rosovsky RP Brenner SK et al Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically ill patients with COVID-19 Annals of internal medicine 20211745622 3210.7326/M20-6739786367933493012Search in Google Scholar

20Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Mignatti A, Gianos E, Cohen M, Sharifova G, Lund JM. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA internal medicine. 2021 Dec 1;181(12):1612-20. Spyropoulos AC Goldin M Giannis D Diab W Wang J Khanijo S Mignatti A Gianos E Cohen M Sharifova G Lund JM Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial JAMA internal medicine 2021 Dec 1181121612 2010.1001/jamainternmed.2021.6203849893434617959Search in Google Scholar

21Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Turgeon AF, Kornblith LZ. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. The New England Journal of Medicine. 2021 Aug 4;385(9):777-89. Goligher EC Bradbury CA McVerry BJ Lawler PR Berger JS Gong MN Carrier M Reynolds HR Kumar A Turgeon AF Kornblith LZ Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 The New England Journal of Medicine 2021 Aug 43859777 8910.1056/NEJMoa2103417836259234351722Search in Google Scholar

22Mazloomzadeh S, Khaleghparast S, Ghadrdoost B, Mousavizadeh M, Baay MR, Noohi F, Sharifnia H, Ahmadi A, Tavan S, Alamdari NM, Fathi M. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. Jama. 2021 Apr 27;325(16):1620-30. Mazloomzadeh S Khaleghparast S Ghadrdoost B Mousavizadeh M Baay MR Noohi F Sharifnia H Ahmadi A Tavan S Alamdari NM Fathi M Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial Jama 2021 Apr 27325161620 3010.1001/jama.2021.4152797483533734299Search in Google Scholar

23Grootaert V, Willems L, Debaveye Y, Meyfroidt G, Spriet I. Augmented renal clearance in the critically ill: how to assess kidney function. Ann Pharmacother. 2012;46(7-8):952-9. Grootaert V Willems L Debaveye Y Meyfroidt G Spriet I Augmented renal clearance in the critically ill: how to assess kidney function Ann Pharmacother 2012467-8952 910.1345/aph.1Q70822693271Search in Google Scholar

24National Institutes of Health. Clinical spectrum of SARS-CoV-2 infection. 2020. Available at: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/. Accessed on December 20. National Institutes of Health Clinical spectrum of SARS-CoV-2 infection 2020 Available at https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/. Accessed on December 20Search in Google Scholar

25Schünemann HJ, Cushman M, Burnett AE, Kahn SR, Beyer-Westendorf J, Spencer FA, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood advances. 2018;2(22):3198-225. Schünemann HJ Cushman M Burnett AE Kahn SR Beyer-Westendorf J Spencer FA et al American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients Blood advances 20182223198 22510.1182/bloodadvances.2018022954625891030482763Search in Google Scholar

26Cohoon KP, Mahé G, Tafur AJ, Spyropoulos AC. Emergence of institutional antithrombotic protocols for coronavirus 2019. Research and Practice in Thrombosis and Haemostasis. 2020;4(4):510. Cohoon KP Mahé G Tafur AJ Spyropoulos AC Emergence of institutional antithrombotic protocols for coronavirus 2019 Research and Practice in Thrombosis and Haemostasis 20204451010.1002/rth2.12358726752432542211Search in Google Scholar

27Meyer G, Planquette B. Incidental venous thromboembolism, detected by chance, but still venous thromboembolism. Eur Respiratory Soc; 2020. Meyer G Planquette B Incidental venous thromboembolism, detected by chance, but still venous thromboembolism Eur Respiratory Soc; 202010.1183/13993003.00028-202032029648Search in Google Scholar

28Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32-5. Youden WJ Index for rating diagnostic tests Cancer 19503132 510.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3Search in Google Scholar

29Kucher N, Kohler HP, Dornhöfer T, Wallmann D, Lämmle B. Accuracy of d‐dimer/fibrinogen ratio to predict pulmonary embolism: a prospective diagnostic study. Journal of Thrombosis and Haemostasis. 2003;1(4):708-13. Kucher N Kohler HP Dornhöfer T Wallmann D Lämmle B Accuracy of d‐dimer/fibrinogen ratio to predict pulmonary embolism: a prospective diagnostic study Journal of Thrombosis and Haemostasis 200314708 1310.1046/j.1538-7836.2003.00145.xSearch in Google Scholar

30Yockey RD. SPSS demystified: A simple guide and reference: Routledge; 2016. Yockey RD SPSS demystified: A simple guide and reference: Routledge 201610.4324/9781315508535Search in Google Scholar

31Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of thrombosis and haemostasis. 2020 Apr;18(4):844-7. Tang N Li D Wang X Sun Z Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Journal of thrombosis and haemostasis 2020 Apr184844 710.1111/jth.14768Search in Google Scholar

32Mousavi S, Moradi M, Khorshidahmad T, Motamedi M. Anti-Inflammatory Effects of Heparin and Its Derivatives: A Systematic Review. Advances in Pharmacological Sciences. 2015 May 12;2015:507151-. Mousavi S Moradi M Khorshidahmad T Motamedi M Anti-Inflammatory Effects of Heparin and Its Derivatives: A Systematic Review Advances in Pharmacological Sciences 2015 May 12201550715110.1155/2015/507151444364426064103Search in Google Scholar

33Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Nigoghossian CD, Ageno W, Madjid M, Guo Y, Tang LV. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. Journal of the American college of cardiology. 2020 Jun 16;75(23):2950-73. Bikdeli B Madhavan MV Jimenez D Chuich T Dreyfus I Driggin E Nigoghossian CD Ageno W Madjid M Guo Y Tang LV COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review Journal of the American college of cardiology 2020 Jun 1675232950 7310.1016/j.jacc.2020.04.031716488132311448Search in Google Scholar

34Masias C, Vasu S, Cataland S. None of the above: thrombotic microangiopathy beyond TTP and HUS. Blood. 2017;129(21):2857. Masias C Vasu S Cataland S None of the above: thrombotic microangiopathy beyond TTP and HUS Blood 201712921285710.1182/blood-2016-11-74310428416509Search in Google Scholar

35Nadkarni GN, Lala A, Bagiella E, Chang HL, Moreno PR, Pujadas E, et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. Journal of the American College of Cardiology. 2020;76(16):1815-26. Nadkarni GN Lala A Bagiella E Chang HL Moreno PR Pujadas E et al Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19 Journal of the American College of Cardiology 202076161815 2610.1016/j.jacc.2020.08.041744965532860872Search in Google Scholar

36Robinson S, Zincuk A, Strøm T, Larsen TB, Rasmussen B, Toft P. Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial. Critical Care. 2010;14(2):1-7. Robinson S Zincuk A Strøm T Larsen TB Rasmussen B Toft P Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial Critical Care 20101421 710.1186/cc8924288715120298591Search in Google Scholar

37Umemura Y, Yamakawa K, Ogura H, Yuhara H, Fujimi S. Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta‐analysis of randomized controlled trials. Journal of Thrombosis and Haemostasis. 2016 Mar;14(3):518-30. Umemura Y Yamakawa K Ogura H Yuhara H Fujimi S Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta‐analysis of randomized controlled trials Journal of Thrombosis and Haemostasis 2016 Mar143518 3010.1111/jth.1323026670422Search in Google Scholar

38Mattioli M, Benfaremo D, Mancini M, Mucci L, Mainquà P, Polenta A, et al. Safety of intermediate dose of low molecular weight heparin in COVID-19 patients. Journal of thrombosis and thrombolysis. 2021;51(2):286-92. Mattioli M Benfaremo D Mancini M Mucci L Mainquà P Polenta A et al Safety of intermediate dose of low molecular weight heparin in COVID-19 patients Journal of thrombosis and thrombolysis 2021512286 9210.1007/s11239-020-02243-z742600732794132Search in Google Scholar

39Arabi YM, Al-Hameed F, Burns KE, Mehta S, Alsolamy SJ, Alshahrani MS, et al. Adjunctive intermittent pneumatic compression for venous thromboprophylaxis. New England Journal of Medicine. 2019;380(14):1305-15. Arabi YM Al-Hameed F Burns KE Mehta S Alsolamy SJ Alshahrani MS et al Adjunctive intermittent pneumatic compression for venous thromboprophylaxis New England Journal of Medicine 2019380141305 1510.1056/NEJMoa181615030779530Search in Google Scholar